Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.69 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 8/20 | 0.36 |
| ▸ | AKT2 | P31751 | 4/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18188070 | 0.80 | MAP4K4 (0.71) | MAP4K4MKNK1MKNK2NOS3NOS1 | |
| SCHEMBL4582566 | 0.79 | MKNK1 (0.59) | MAP4K4MKNK1MKNK2NOS3NOS1 | |
| SCHEMBL4582784 | 0.79 | MAP4K4 (0.69) | MAP4K4MKNK1MKNK2NOS3NOS1 | |
| SCHEMBL1148699 | 0.77 | MAP4K4 (0.66) | MAP4K4MKNK1MKNK2NOS3NOS1 | |
| SCHEMBL27500767 | 0.76 | MAP4K4 (0.65) | MAP4K4MKNK1MKNK2AKT1AKT2 | |
| SCHEMBL4582430 | 0.75 | CHEK2 (0.44) | MAP4K4FYNDHFR | |
| SCHEMBL3140455 | 0.75 | MAP4K4 (0.63) | MAP4K4MKNK1MKNK2NOS3NOS2 | |
| SCHEMBL8738130 | 0.75 | MAP4K4 (0.63) | MAP4K4MKNK1MKNK2NOS3NOS1 | |
| SCHEMBL15394275 | 0.75 | MAP4K4 (0.63) | MAP4K4MKNK1MKNK2NOS3NOS1 | |
| SCHEMBL10062975 | 0.73 | MAP4K4 (0.59) | MAP4K4MKNK1MKNK2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | KIT, PRKCH, PRKCB | MAP4K4 354/4885MKNK1 417/4885MKNK2 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.